Loading...
Loading...
According to a research report published this morning, Morgan Stanley has increased Watson Pharmaceuticals'
WPI PT from $65 to $84.
Morgan Stanley said in the report, "We are raising our pro forma '13-‘15E EPS by 30%- 60% and raising our PT by 30% to $84 (10.5x pro forma ‘13E of $8.01) on the heels of the strategically compelling and highly-accretive Actavis deal."
Morgan Stanley maintains its Overweight rating on Watson Pharmaceuticals, which closed yesterday at $69.69.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in